Actelion's Uptravi Given Positive Opinion By CHMP
This article was originally published in Scrip
Actelion Pharmaceuticals Ltd.'s orally active selective prostacyclin agonist Uptravi (selexipag) has been recommended for marketing in Europe for the treatment of pulmonary arterial hypertension by the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use (CHMP), just over a month after the product gained a marketing approval in the US.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.